Characterization and potential clinical applications of autoantibodies against cytokines

Cytokine and Growth Factor Reviews

Volumn 20, Issue 1, 2009, Pages 61-75

  de Lemos Rieper, Carina ^a   Galle, Pia ^a   Hansen, Morten Bagge ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Anti cytokine vaccination; Binding proteins; Cytokine autoantibodies; Cytokine deficiency; Immune deficiency

Indexed keywords

AUTOANTIBODY; CYTOKINE; IMMUNOGLOBULIN; INTERFERON;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; CHRONIC DISEASE; CLINICAL FEATURE; HUMAN; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; LUNG DISEASE; METHODOLOGY; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUANTITATIVE STUDY; REVIEW; T LYMPHOCYTE; VACCINATION;

ALLERGY AND IMMUNOLOGY; ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; CYTOKINES; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS; MODELS, BIOLOGICAL; PROTEIN BINDING;

EID: 60949092700     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2009.01.003     Document Type: Review

References (212)

1. Abe Y., Horiuchi A., Miyake M., and Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 139 (1994) 5-19
2. Bendtzen K., Hansen M.B., Ross C., and Svenson M. High-avidity autoantibodies to cytokines. Immunol Today 19 (1998) 209-211
3. Hansen M.B., Svenson M., Diamant M., Abell K., and Bendtzen K. Interleukin-6 autoantibodies: possible biological and clinical significance. Leukemia 9 (1995) 1113-1115
4. Hansen M.B. Human cytokine autoantibodies. Characteristics, test procedures and possible physiological and clinical significance. APMIS Suppl 59 (1996) 1-33
5. van der Meide P.H., and Schellekens H. Anti-cytokine autoantibodies: epiphenomenon or critical modulators of cytokine action. Biotherapy 10 (1997) 39-48
6. von W.P., Freund M., Dahle S., Jakschies D., Poliwode H., and Deicher H. Immunogenicity of different types of interferons in the treatment of hairy-cell leukemia. N Engl J Med 319 (1988) 1226-1227
7. Vallbracht A., Treuner J., Manncke K.H., and Niethammer D. Autoantibodies against human beta interferon following treatment with interferon. J Interferon Res 2 (1982) 107-110
8. Steis R.G., Smith J.W., Urba W.J., Clark J.W., Itri L.M., Evans L.M., et al. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318 (1988) 1409-1413
9. Kirchner H., Korfer A., Evers P., Szamel M.M., Knuver-Hopf J., Mohr H., et al. The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2. Cancer 67 (1991) 1862-1864
10. Dummer R., Muller W., Nestle F., Wiede J., Dues J., Lechner W., et al. Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients. Cancer 67 (1991) 2300-2304
11. Giannelli G., Antonelli G., Fera G., Del Vecchio S., Riva E., Broccia C., et al. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C. Clin Exp Immunol 97 (1994) 4-9
12. Antonelli G., Bagnato F., Pozzilli C., Simeoni E., Bastianelli S., Currenti M., et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a. J Interferon Cytokine Res 18 (1998) 345-350
13. Antonelli G., Currenti M., Turriziani O., and Dianzani F. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 163 (1991) 882-885
14. Antonelli G., Simeoni E., Currenti M., De Pisa F., Colizzi V., Pistello M., et al. Interferon antibodies in patients with infectious diseases. Anti-interferon antibodies. Biotherapy 10 (1997) 7-14
15. Hansen M.B., Ross C., and Berg K. A sensitive antiviral neutralization bioassay for measuring antibodies to interferons. J Immunol Methods 127 (1990) 241-248
16. Turano A., Balsari A., Viani E., Landolfo S., Zanoni L., Gargiulo F., et al. Natural human antibodies to gamma interferon interfere with the immunomodulating activity of the lymphokine. Proc Natl Acad Sci USA 89 (1992) 4447-4451
17. Trown P.W., Kramer M.J., Dennin Jr. R.A., Connell E.V., Palleroni A.V., Quesada J., et al. Antibodies to human leucocyte interferons in cancer patients. Lancet 1 (1983) 81-84
18. Suit B.E., Axelrod D., Moutsopoulos H.M., Decker J.L., and Hooks J.J. Detection of anti-interferon antibodies in systemic lupus erythematosus. Clin Exp Rheumatol 1 (1983) 133-135
19. Prummer O., Frickhofen N., Digel W., Heimpel H., and Porzsolt F. Spontaneous interferon-alpha antibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas. Ann Hematol 62 (1991) 76-80
20. Paul S., Said S.I., Thompson A.B., Volle D.J., Agrawal D.K., Foda H., et al. Characterization of autoantibodies to vasoactive intestinal peptide in asthma. J Neuroimmunol 23 (1989) 133-142
21. Panem S., Check I.J., Henriksen D., and Vilcek J. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J Immunol 129 (1982) 1-3
22. Mogensen K.E., Daubas P., Gresser I., Sereni D., and Varet B. Patient with circulating antibodies to alpha-interferon. Lancet 2 (1981) 1227-1228
23. Pozzetto B., Mogensen K.E., Tovey M.G., and Gresser I. Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J Infect Dis 150 (1984) 707-713
24. De Maeyer-Guignard J., Cachard-Thomas A., and De Maeyer-Guignard E. Naturally occurring anti-interferon antibodies in Lou/c rats. J Immunol 133 (1984) 775-778
25. De Maeyer-Guignard J., and De Maeyer-Guignard E. Natural antibodies to interferon-alpha and interferon-beta are a common feature of inbred mouse strains. J Immunol 136 (1986) 1708-1711
26. Hansen M.B., Nielsen S.E., and Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119 (1989) 203-210
27. Ross C., Hansen M.B., Schyberg T., and Berg K. Autoantibodies versus the human interferon system. Scand J Immunol 30 (1989) 647
28. Ross C., Hansen M.B., Schyberg T., and Berg K. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin Exp Immunol 82 (1990) 57-62
29. Svenson M., Poulsen L.K., Fomsgaard A., and Bendtzen K. IgG autoantibodies against interleukin 1 alpha in sera of normal individuals. Scand J Immunol 29 (1989) 489-492
30. Fomsgaard A., Svenson M., and Bendtzen K. Auto-antibodies to tumour necrosis factor alpha in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections. Scand J Immunol 30 (1989) 219-223
31. Hansen M.B., Svenson M., Diamant M., and Bendtzen K. Anti-interleukin-6 antibodies in normal human serum. Scand J Immunol 33 (1991) 777-781
32. Peichl P., Pursch E., Broll H., and Lindley I.J. Anti-IL-8 autoantibodies and complexes in rheumatoid arthritis: polyclonal activation in chronic synovial tissue inflammation. Rheumatol Int 18 (1999) 141-145
33. Svenson M., Hansen M.B., Ross C., Diamant M., Rieneck K., Nielsen H., et al. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 91 (1998) 2054-2061
34. Ross C., Svenson M., Hansen M.B., Vejlsgaard G.L., and Bendtzen K. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J Clin Invest 95 (1995) 1974-1978
35. Ross C., Svenson M., Nielsen H., Lundsgaard C., Hansen M.B., and Bendtzen K. Increased in vivo antibody activity against interferon alpha, interleukin-1alpha, and interleukin-6 after high-dose Ig therapy. Blood 90 (1997) 2376-2380
36. Svenson M., Hansen M.B., and Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 92 (1993) 2533-2539
37. Crabtree J.E., Peichl P., Wyatt J.I., Stachl U., and Lindley I.J. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol 37 (1993) 65-70
38. Bonfanti C., Caruso A., Bakhiet M., Olsson T., Turano A., and Kristensson K. Increased levels of antibodies to IFN-gamma in human and experimental African trypanosomiasis. Scand J Immunol 41 (1995) 49-52
39. Caruso A., Bonfanti C., Colombrita D., De Francesco M., De Rango C., Foresti I., et al. Natural antibodies to IFN-gamma in man and their increase during viral infection. J Immunol 144 (1990) 685-690
40. Bost K.L., Hahn B.H., Saag M.S., Shaw G.M., Weigent D.A., and Blalock J.E. Individuals infected with HIV possess antibodies against IL-2. Immunology 65 (1988) 611-615
41. Antonelli G., and Dianzani F. Antibodies to interferon alpha in patients. Arch Virol Suppl 8 (1993) 271-277
42. Bendtzen K., Svenson M., and Hansen M.B. GM-CSF autoantibodies in pulmonary alveolar proteinosis. N Engl J Med 356 (2007) 2001
43. Meager A., Wadhwa M., Dilger P., Bird C., Thorpe R., Newsom-Davis J., et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 132 (2003) 128-136
44. Meager A., Visvalingam K., Peterson P., Moll K., Murumagi A., Krohn K., et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 3 (2006) e289
45. Forslind K., Svensson B., Svenson M., and Bendtzen K. Anti-IL-1alpha autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 30 (2001) 167-168
46. Takasaki J., and Ogawa Y. Anti-interleukin-8 autoantibody in the tracheobronchial aspirate of infants with chronic lung disease. Pediatr Int 43 (2001) 48-52
47. Kurdowska A., Noble J.M., Steinberg K.P., Ruzinski J.T., Hudson L.D., and Martin T.R. Anti-interleukin 8 autoantibody: interleukin 8 complexes in the acute respiratory distress syndrome. Relationship between the complexes and clinical disease activity. Am J Respir Crit Care Med 163 (2001) 463-468
48. Kurdowska A.K., Noble J.M., and Adcock J.E. Interleukin-8 and anti-interleukin-8 autoantibodies in gingival cervicular fluid from patients with periodontitis. J Periodontal Res 38 (2003) 73-78
49. Krupa A., Kato H., Matthay M.A., and Kurdowska A.K. Proinflammatory activity of anti-IL-8 autoantibody:IL-8 complexes in alveolar edema fluid from patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 286 (2004) L1105-L1113
50. Lokshin A.E., Winans M., Landsittel D., Marrangoni A.M., Velikokhatnaya L., Modugno F., et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 102 (2006) 244-251
51. Allen T.C., Fudala R., Nash S.E., and Kurdowska A. Anti-interleukin 8 autoantibody:interleukin 8 immune complexes visualized by laser confocal microscopy in injured lung. Arch Pathol Lab Med 131 (2007) 452-456
52. Puel A., Picard C., Lorrot M., Pons C., Chrabieh M., Lorenzo L., et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol 180 (2008) 647-654
53. Krupa A., Walencka M.J., Shrivastava V., Loyd T., Fudala R., Frevert C.W., et al. Anti-KC autoantibody:KC complexes cause severe lung inflammation in mice via IgG receptors. Am J Respir Cell Mol Biol 37 (2007) 532-543
54. Uchida K., Beck D.C., Yamamoto T., Berclaz P.Y., Abe S., Staudt M.K., et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 356 (2007) 567-579
55. Graudal N.A., Svenson M., Tarp U., Garred P., Jurik A.G., and Bendtzen K. Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome. Ann Rheum Dis 61 (2002) 598-602
56. Menetrier-Caux C., Briere F., Jouvenne P., Peyron E., Peyron F., and Banchereau J. Identification of human IgG autoantibodies specific for IL-10. Clin Exp Immunol 104 (1996) 173-179
57. Hoflich C., Sabat R., Rosseau S., Temmesfeld B., Slevogt H., Docke W.D., et al. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 103 (2004) 673-675
58. Kampmann B., Hemingway C., Stephens A., Davidson R., Goodsall A., Anderson S., et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest 115 (2005) 2480-2488
59. Patel S.Y., Ding L., Brown M.R., Lantz L., Gay T., Cohen S., et al. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol 175 (2005) 4769-4776
60. Zhang W., Liu J.L., Meager A., Newsom-Davis J., and Willcox N. Autoantibodies to IL-12 in myasthenia gravis patients with thymoma; effects on the IFN-gamma responses of healthy CD4+ T cells. J Neuroimmunol 139 (2003) 102-108
61. Shiono H., Wong Y.L., Matthews I., Liu J.L., Zhang W., Sims G., et al. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int Immunol 15 (2003) 903-913
62. Thomassen M.J., Yi T., Raychaudhuri B., Malur A., and Kavuru M.S. Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect. Clin Immunol 95 (2000) 85-92
63. Bonfield T.L., Russell D., Burgess S., Malur A., Kavuru M.S., and Thomassen M.J. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 27 (2002) 481-486
64. Uchida K., Nakata K., Trapnell B.C., Terakawa T., Hamano E., Mikami A., et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 103 (2004) 1089-1098
65. Suzuki H., Takemura H., Yoshizaki K., Koishihara Y., Ohsugi Y., Okano A., et al. IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis. J Immunol 152 (1994) 935-942
66. Hansen M.B., Andersen V., Rohde K., Florescu A., Ross C., Svenson M., et al. Cytokine autoantibodies in rheumatoid arthritis. Scand J Rheumatol 24 (1995) 197-203
67. Muller K., Hansen M.B., Zak M., Nielsen S., Pedersen F.K., de Nully P., et al. Autoantibodies to IL-1 alpha in sera from umbilical cords, children, and adults, and from patients with juvenile chronic arthritis. Scand J Rheumatol 25 (1996) 164-167
68. Capini C.J., Richardson M.W., Hendel H., Sverstiuk A., Mirchandani J., Regulier E.G., et al. Autoantibodies to TNFalpha in HIV-1 infection: prospects for anti-cytokine vaccine therapy. Biomed Pharmacother 55 (2001) 23-31
69. Sjowall C., Ernerudh J., Bengtsson A.A., Sturfelt G., and Skogh T. Reduced anti-TNFalpha autoantibody levels coincide with flare in systemic lupus erythematosus. J Autoimmunol 22 (2004) 315-323
70. Bagnato F., Clemenzi A., Scagnolari C., Strizzi L., Di Pasquale A., Bellomi F., et al. Neutralizing antibodies against endogenous interferon in myasthenia gravis patients. Eur Cytokine Netw 15 (2004) 24-29
71. Jouvenne P., Fossiez F., Garrone P., Djossou O., Banchereau J., and Miossec P. Increased incidence of neutralizing autoantibodies against interleukin-1 alpha (IL-1 alpha) in nondestructive chronic polyarthritis. J Clin Immunol 16 (1996) 283-290
72. Elkarim R.A., Mustafa M., Kivisakk P., Link H., and Bakhiet M. Cytokine autoantibodies in multiple sclerosis, aseptic meningitis and stroke. Eur J Clin Invest 28 (1998) 295-299
73. von W.P., Jakschies D., Hartung K., and Deicher H. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol Int 8 (1988) 225-230
74. Caruso A., Viani E., Tiberio L., Pollara P., Monti E., Bonfanti C., et al. Inhibition of the biological activity of human interferon-gamma by antipeptide antibodies. J Interferon Res 12 (1992) 49-54
75. Takemura H., Suzuki H., Yoshizaki K., Ogata A., Yuhara T., Akama T., et al. Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum 35 (1992) 940-943
76. Suzuki H., Kamimura J., Ayabe T., and Kashiwagi H. Demonstration of neutralizing autoantibodies against IL-1 alpha in sera from patients with rheumatoid arthritis. J Immunol 145 (1990) 2140-2146
77. Suzuki H., Ayabe T., Kamimura J., and Kashiwagi H. Anti-IL-1 alpha autoantibodies in patients with rheumatic diseases and in healthy subjects. Clin Exp Immunol 85 (1991) 407-412
78. Suzuki H., Akama T., Okane M., Kono I., Matsui Y., Yamane K., et al. Interleukin-1-inhibitory IgG in sera from some patients with rheumatoid arthritis. Arthritis Rheum 32 (1989) 1528-1538
79. Sunder-Plassmann G., Kapiotis S., Gasche C., and Klaar U. Functional characterization of cytokine autoantibodies in chronic renal failure patients. Kidney Int 45 (1994) 1484-1488
80. Sunder-Plassmann G., Sedlacek P.L., Sunder-Plassmann R., Derfler K., Swoboda K., Fabrizii V., et al. Anti-interleukin-1 alpha autoantibodies in hemodialysis patients. Kidney Int 40 (1991) 787-791
81. Peichl P., Ceska M., Broell H., Effenberger F., and Lindley I.J. Human neutrophil activating peptide/interleukin 8 acts as an autoantigen in rheumatoid arthritis. Ann Rheum Dis 51 (1992) 19-22
82. Nielsen O.H., Horn T., Prifti S., Peichl P., Scheibel J.H., and Lindley I.J. Gastric mucosal interleukin-8 and IL-8 antibody concentrations related to prevailing Helicobacter pylori infections. A Danish-Albanian study. Dan Med Bull 46 (1999) 249-252
83. Paul S., Heinz-Erian P., and Said S.I. Autoantibody to vasoactive intestinal peptide in human circulation. Biochem Biophys Res Commun 130 (1985) 479-485
84. Paul S., and Said S.I. Human autoantibody to vasoactive intestinal peptide: increased incidence in muscular exercise. Life Sci 43 (1988) 1079-1084
85. Hansen M.B., Svenson M., and Bendtzen K. Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN-alpha in normal human sera. Clin Exp Immunol 88 (1992) 559-562
86. Galle P., Svenson M., Bendtzen K., and Hansen M.B. High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. Eur J Immunol 34 (2004) 3267-3275
87. Hansen M.B., Svenson M., Abell K., Varming K., Nielsen H.P., Bertelsen A., et al. Sex- and age-dependency of IgG auto-antibodies against IL-1 alpha in healthy humans. Eur J Clin Invest 24 (1994) 212-218
88. Svenson M., Hansen M.B., Kayser L., Rasmussen A.K., Reimert C.M., and Bendtzen K. Effects of human anti-IL-1 alpha autoantibodies on receptor binding and biological activities of IL-1. Cytokine 4 (1992) 125-133
89. Svenson M., Bagge H.M., and Bendtzen K. Distribution and characterization of autoantibodies to interleukin 1 alpha in normal human sera. Scand J Immunol 32 (1990) 695-701
90. Liu E., and Eisenbarth G.S. Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays. Clin Immunol 125 (2007) 120-126
91. Hansen M.B., Svenson M., Abell K., Yasukawa K., Diamant M., and Bendtzen K. Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors. Eur J Immunol 25 (1995) 348-354
92. Colotta F., Re F., Muzio M., Bertini R., Polentarutti N., Sironi M., et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261 (1993) 472-475
93. Mantovani A., Locati M., Vecchi A., Sozzani S., and Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 22 (2001) 328-336
94. Bendtzen K., Hansen M.B., Ross C., and Svenson M. Detection of autoantibodies to cytokines. Mol Biotechnol 14 (2000) 251-261
95. Hansen M.B., Svenson M., Diamant M., and Bendtzen K. High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine 5 (1993) 72-80
96. Galle P., Hougs L., Barington T., Svenson M., Svejgaard A., Thomsen A.R., et al. Knocking out IL-6 by vaccination. Eur J Immunol 34 (2004) 291-300
97. Hansen M.B., Galle P., Salomo M., Svenson M., Dickmeiss E., and Gimsing P. Transfusion-related inhibition of cytokines (TRICK). Experimental transfer of neutralizing autoantibodies to interleukin-6 by plasma transfusions. Vox Sang 92 (2007) 213-223
98. Richards P.J., Nowell M.A., Horiuchi S., McLoughlin R.M., Fielding C.A., Grau S., et al. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum 54 (2006) 1662-1672
99. Rose-John S., Scheller J., Elson G., and Jones S.A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80 (2006) 227-236
100. Hansen M.B., Svenson M., Diamant M., Ross C., and Bendtzen K. Interleukin-6 (IL-6) autoantibodies and blood IL-6 measurements. Blood 85 (1995) 1145
101. Zhang L., Barker J.M., Babu S., Su M., Stenerson M., Cheng M., et al. A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin Immunol 125 (2007) 131-137
102. Svenson M., Hansen M.B., Heegaard P., Abell K., and Bendtzen K. Specific binding of interleukin 1 (IL-1) beta and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I. Cytokine 5 (1993) 427-435
103. Brochier J., Legouffe E., Liautard J., Gaillard J.P., Mao L.Q., Bataille R., et al. Immunomodulating IL-6 activity by murine monoclonal antibodies. Int J Immunopharmacol 17 (1995) 41-48
104. Beck J.T., Hsu S.M., Wijdenes J., Bataille R., Klein B., Vesole D., et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330 (1994) 602-605
105. Bataille R., Zhang X.G., Wijdenes J., Schved J.F., and Klein B. Effects of an anti-interleukin-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia. Med Oncol Tumor Pharmacother 10 (1993) 185-188
106. Ndubuisi M.I., Patel K., Rayanade R.J., Mittelman A., May L.T., and Sehgal P.B. Distinct classes of chaperoned IL-6 in human blood: differential immunological and biological availability. J Immunol 160 (1998) 494-501
107. May L.T., Ndubuisi M.I., Patel K., and Garcia D. Interleukin-6 chaperones in blood. Ann N Y Acad Sci 762 (1995) 120-128
108. Mihara M., Koishihara Y., Fukui H., Yasukawa K., and Ohsugi Y. Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice. Immunology 74 (1991) 55-59
109. Bataille R., Barlogie B., Lu Z.Y., Rossi J.F., Lavabre-Bertrand T., Beck T., et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86 (1995) 685-691
110. Montero-Julian F.A., Gautherot E., Wijdenes J., Klein B., and Brailly H. Pharmacokinetics of interleukin-6 during therapy with anti-interleukin-6 monoclonal antibodies: enhanced clearance of interleukin-6 by a combination of three anti-interleukin-6 antibodies. J Interferon Res 14 (1994) 301-302
111. May L.T., Viguet H., Kenney J.S., Ida N., Allison A.C., and Sehgal P.B. High levels of "complexed" interleukin-6 in human blood. J Biol Chem 267 (1992) 19698-19704
112. Ciapponi L., Maione D., Scoumanne A., Costa P., Hansen M.B., Svenson M., et al. Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. Nat Biotechnol 15 (1997) 997-1001
113. Bossu P., Neumann D., Del Giudice E., Ciaramella A., Gloaguen I., Fantuzzi G., et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci USA 100 (2003) 14181-14186
114. Dalum I., Butler D.M., Jensen M.R., Hindersson P., Steinaa L., Waterston A.M., et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 17 (1999) 666-669
115. Le Buanec H., Delavallee L., Bessis N., Paturance S., Bizzini B., Gallo R., et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci USA 103 (2006) 19442-19447
116. Rad F.H., Le Buanec H., Paturance S., Larcier P., Genne P., Ryffel B., et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA 104 (2007) 2837-2842
117. Richard M., Grencis R.K., Humphreys N.E., Renauld J.C., and Van S.J. Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. Proc Natl Acad Sci USA 97 (2000) 767-772
118. Rohn T.A., Jennings G.T., Hernandez M., Grest P., Beck M., Zou Y., et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 36 (2006) 2857-2867
119. Svenson M., Hansen M.B., Thomsen A.R., Diamant M., Nansen A., Rieneck K., et al. Cytokine vaccination: neutralising IL-1alpha autoantibodies induced by immunisation with homologous IL-1alpha. J Immunol Methods 236 (2000) 1-8
120. Uyttenhove C., Arendse B., Stroobant V., Brombacher F., and van Snick J. Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur J Immunol 34 (2004) 3572-3581
121. Kopf M., Le Gros G., Coyle A.J., Kosco-Vilbois M., and Brombacher F. Immune responses of IL-4, IL-5, IL-6 deficient mice. Immunol Rev 148 (1995) 45-69
122. Tsiodras S., Samonis G., Boumpas D.T., and Kontoyiannis D.P. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 83 (2008) 181-194
123. Strangfeld A., and Listing J. Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 20 (2006) 1181-1195
124. Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371 (2008) 998-1006
125. Smolen J.S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371 (2008) 987-997
126. Bustamante J., Boisson-Dupuis S., Jouanguy E., Picard C., Puel A., Abel L., et al. Novel primary immunodeficiencies revealed by the investigation of paediatric infectious diseases. Curr Opin Immunol 20 (2008) 39-48
127. May L.T., Neta R., Moldawer L.L., Kenney J.S., Patel K., and Sehgal P.B. Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J Immunol 151 (1993) 3225-3236
128. Aston R., Cowden W.B., and Ada G.L. Antibody-mediated enhancement of hormone activity. Mol Immunol 26 (1989) 435-446
129. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368 (1994) 339-342
130. Wallenius V., Wallenius K., Ahren B., Rudling M., Carlsten H., Dickson S.L., et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8 (2002) 75-79
131. Steensberg A., Fosgerau K., Galle P.S., Hansen T., Albrechtsen A., De Lemos Rieper C., et al. Increased levels of auto-reactive interleukin-6 antibodies in patients with type 2 diabetes. Diabetes 56 (2007) A322
132. McInnes I.B., and Liew F.Y. Cytokine networks-towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 1 (2005) 31-39
133. Nishimoto N., and Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2 (2006) 619-626
134. Wildbaum G., Nahir M.A., and Karin N. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity 19 (2003) 679-688
135. Spohn G., and Bachmann M.F. Therapeutic vaccination to block receptor-ligand interactions. Expert Opin Biol Ther 3 (2003) 469-476
136. Bachmann M.F., and Dyer M.R. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov 3 (2004) 81-88
137. Dyer M.R., Renner W.A., and Bachmann M.F. A second vaccine revolution for the new epidemics of the 21st century. Drug Discov Today 11 (2006) 1028-1033
138. Gringeri A., Santagostino E., Mannucci P.M., Tradati F., Cultraro D., Buzzi A., et al. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization. J Acquir Immune Defic Syndrome 7 (1994) 978-988
139. Bendtzen K., Geborek P., Svenson M., Larsson L., Kapetanovic M.C., and Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 54 (2006) 3782-3789
140. Rettig M.B. Interleukin-6: an antagonizing problem becomes a solution. Nat Biotechnol 15 (1997) 952-953
141. Galle P., Jensen L., Andersson C., Cuzzocrea S., Di Paola R., Nicoletti F., et al. Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation. Int Immunopharmacol 7 (2007) 1704-1713
142. Delavallee L., Le Buanec H., Bessis N., Assier E., Denys A., Bizzini B., et al. Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNF alpha. Ann Rheum Dis 67 (2008) 1332-1338
143. De Benadetti F., Pignatti P., Vivarelli M., Meazza C., Ciliberto G., Savino R., et al. In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6-transgenic mice with a hIL-6 receptor antagonist. J Immunol 166 (2001) 4334-4340
144. Delavallee L., Assier E., Denys A., Falgarone G., Zagury J.F., Muller S., et al. Vaccination with cytokines in autoimmune diseases. Ann Med 40 (2008) 343-351
145. van de Vosse E., and van Agtmael M.A. Targets of anticytokine therapy and the risk of infections in humans and mice. Curr Opin Rheumatol 19 (2007) 626-635
146. Bachmann M.F., Nussberger J., Tissot A.C., and Jennings G.T. Reply to 'blood pressure vaccine shot down by safety concerns'. Nat Med 12 (2006) 270
147. Homann C., Hansen M.B., Graudal N., Hasselqvist P., Svenson M., Bendtzen K., et al. Anti-interleukin-6 autoantibodies in plasma are associated with an increased frequency of infections and increased mortality of patients with alcoholic cirrhosis. Scand J Immunol 44 (1996) 623-629
148. Zagury D., Lecoq H., Gervi I., Le Buanec H., Zagury J.F., Bizzini B., et al. Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum-an adjuvant to antiretroviral tritherapy. Biomed Pharmacother 53 (1999) 90-92
149. Zagury D., Burny A., and Gallo R.C. Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines. Proc Natl Acad Sci USA 98 (2001) 8024-8029
150. Zagury D., and Gallo R.C. Anti-cytokine Ab immune therapy: present status and perspectives. Drug Discov Today 9 (2004) 72-81
151. Waterston A.M., Gumbrell L., Bratt T., Waller S., Gustav-Aspland J., L'hermenier C., et al. Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer. Cancer Immunol Immunother 54 (2005) 848-857
152. Kearney J.F. Formation of autoantibodies, including anti-cytokine antibodies, is a hallmark of the immune response of early B cells. J Interferon Res 14 (1994) 151-152
153. Strobel P., Murumagi A., Klein R., Luster M., Lahti M., Krohn K., et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol 211 (2007) 563-571
154. van Rietschoten J.G., Verzijlbergen K.F., Gringhuis S.I., van der Pouw Kraan T.C., Bayley J.P., Wierenga E.A., et al. Differentially methylated alleles in a distinct region of the human interleukin-1alpha promoter are associated with allele-specific expression of IL-1alpha in CD4+ T cells. Blood 108 (2006) 2143-2149
155. Blencowe B.J. Alternative splicing: new insights from global analyses. Cell 126 (2006) 37-47
156. Soreq L., Gilboa-Geffen A., Berrih-Aknin S., Lacoste P., Darvasi A., Soreq E., et al. Identifying alternative hyper-splicing signatures in MG-thymoma by exon arrays. PLoS ONE 3 (2008) e2392
157. Chatterjee M., Osborne J., Bestetti G., Chang Y., and Moore P.S. Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science 298 (2002) 1432-1435
158. Boulanger M.J., Chow D.C., Brevnova E., Martick M., Sandford G., Nicholas J., et al. Molecular mechanisms for viral mimicry of a human cytokine: activation of gp130 by HHV-8 interleukin-6. J Mol Biol 335 (2004) 641-654
159. Spencer J.V., Cadaoas J., Castillo P.R., Saini V., and Slobedman B. Stimulation of B lymphocytes by cmvIL-10 but not LAcmvIL-10. Virology 374 (2008) 164-169
160. Levine S.J. Mechanisms of soluble cytokine receptor generation. J Immunol 173 (2004) 5343-5348
161. Gresser I., Tovey M.G., Bandu M.E., Maury C., and Brouty-Boye D. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection. J Exp Med 144 (1976) 1305-1315
162. Ireland D.D., Stohlman S.A., Hinton D.R., Atkinson R., and Bergmann C.C. Type I interferons are essential in controlling neurotropic coronavirus infection irrespective of functional CD8 T cells. J Virol 82 (2008) 300-310
163. Huang K.W., Huang Y.C., Tai K.F., Chen B.H., Lee P.H., and Hwang L.H. Dual therapeutic effects of interferon-alpha gene therapy in a rat hepatocellular carcinoma model with liver cirrhosis. Mol Ther 10 (2008) 1681-1687
164. Maher S.G., Sheikh F., Scarzello A.J., Romero-Weaver A.L., Baker D.P., Donnelly R.P., et al. IFN-alpha and IFN-lambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 7 (2008) 1109-1115
165. Prummer O., Seyfarth C., Scherbaum W.A., Drees N., and Porzsolt F. Interferon-alpha antibodies in autoimmune diseases. J Interferon Res 9 Suppl 1 (1989) S67-S74
166. Dorman S.E., and Holland S.M. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J Clin Invest 101 (1998) 2364-2369
167. Monti E., Pozzi A., Tiberio L., Morelli D., Caruso A., Villa M.L., et al. Purification of interleukin-2 antibodies from healthy individuals. Immunol Lett 36 (1993) 261-266
168. Hellmich B., Ciaglo A., Schatz H., and Coakley G. Autoantibodies against granulocyte-macrophage colony stimulating factor and interleukin-3 are rare in patients with Felty's syndrome. Ann Rheum Dis 63 (2004) 862-866
169. Watanabe M., Uchida K., Nakagaki K., Kanazawa H., Trapnell B.C., Hoshino Y., et al. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett 581 (2007) 2017-2021
170. van der P.T., Keogh C.V., Guirao X., Buurman W.A., Kopf M., and Lowry S.F. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 176 (1997) 439-444
171. Fudala R., Krupa A., Stankowska D., Allen T.C., and Kurdowska A.K. Anti-interleukin-8 autoantibody:interleukin-8 immune complexes in acute lung injury/acute respiratory distress syndrome. Clin Sci (Lond) 114 (2008) 403-412
172. Stankowska D.L., Fudala R., and Kurdowska A.K. Mechanism of epithelial injury triggered by anti-IL-8 autoantibody:IL-8 immune complexes. Proc Am Thorac Soc 5 (2008) 365-366
173. Havell E.A. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 143 (1989) 2894-2899
174. Dinarello C.A. Anti-cytokine therapeutics and infections. Vaccine 21 Suppl 2 (2003) S24-S34
175. Bakhiet M., Mustafa M., Zhu J., Harris R., Lindquist L., Link H., et al. Induction of cytokines and anti-cytokine autoantibodies in cerebrospinal fluid (CSF) during experimental bacterial meningitis. Clin Exp Immunol 114 (1998) 398-402
176. Lin F.C., Chang G.D., Chern M.S., Chen Y.C., and Chang S.C. Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis. Thorax 61 (2006) 528-534
177. Wang J.M., Chen Z.G., Colella S., Bonilla M.A., Welte K., Bordignon C., et al. Chemotactic activity of recombinant human granulocyte colony-stimulating factor. Blood 72 (1988) 1456-1460
178. Revoltella R.P., Laricchia-Robbio L., Moscato S., Genua A., and Liberati A.M. Natural and therapy-induced anti-GM-CSF and anti-G-CSF antibodies in human serum. Leuk Lymphoma 26 Suppl 1 (1997) 29-34
179. Hellmich B., Csernok E., Schatz H., Gross W.L., and Schnabel A. Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum 46 (2002) 2384-2391
180. Coscarella A., Liddi R., Di Loreto M., Bach S., Faiella A., van der Meide P.H., et al. The rhGM-CSF-EPO hybrid protein MEN 11300 induces anti-EPO antibodies and severe anaemia in rhesus monkeys. Cytokine 10 (1998) 964-969
181. Chenuaud P., Larcher T., Rabinowitz J.E., Provost N., Cherel Y., Casadevall N., et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 103 (2004) 3303-3304
182. Sipsas N.V., Kokori S.I., Ioannidis J.P., Kyriaki D., Tzioufas A.G., and Kordossis T. Circulating autoantibodies to erythropoietin are associated with human immunodeficiency virus type 1-related anemia. J Infect Dis 180 (1999) 2044-2047
183. Marmont A., Peschle C., Sanguineti M., and Condorelli M. Pure red cell aplasia (PRCA): response of three patients of cyclophosphamide and/or antilymphocyte globulin (ALG) and demonstration of two types of serum IgG inhibitors to erythropoiesis. Blood 45 (1975) 247-261
184. Bertin-Maghit S.M., Capini C.J., Bessis N., Chomilier J., Muller S., Abbas A., et al. Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine 23 (2005) 4228-4235
185. Spohn G., Keller I., Beck M., Grest P., Jennings G.T., and Bachmann M.F. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol 38 (2008) 877-887
186. Ma Y., Hayglass K.T., Becker A.B., Halayko A.J., Basu S., Simons F.E., et al. Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice. Allergy 62 (2007) 675-682
187. Tan G.H., Su J.M., Wang C.C., Huang F.Y., Wang H., Huang Y.H., et al. A recombinant DNA plasmid encoding the human interleukin-5 breaks immunological tolerance and inhibits airway inflammation in a murine model of asthma. Int Arch Allergy Immunol 145 (2008) 313-323
188. Gonzalez G., Crombet T., Catala M., Mirabal V., Hernandez J.C., Gonzalez Y., et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 9 (1998) 431-435
189. Gonzalez G., Crombet T., Neninger E., Viada C., and Lage A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vaccin 3 (2007) 8-13
190. Nair J.R., Bansal S., and Lee K.P. Putting the brakes on angiogenesis through a novel VEGF-KLH (kinoid) vaccine. Expert Rev Vaccines 6 (2007) 491-496
191. Petrovan R.J., Kaplan C.D., Reisfeld R.A., and Curtiss L.K. DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 27 (2007) 1095-1100
192. Hauer A.D., van Puijvelde G.H., Peterse N., de Vos P., van Weel V., van Wanrooij E.J., et al. Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 27 (2007) 2050-2057
193. Niethammer A.G., Xiang R., Becker J.C., Wodrich H., Pertl U., Karsten G., et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8 (2002) 1369-1375
194. Kaplan C.D., Kruger J.A., Zhou H., Luo Y., Xiang R., and Reisfeld R.A. A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. Vaccine 24 (2006) 6994-7002
195. Hauer A.D., Uyttenhove C., de Vos P., Stroobant V., Renauld J.C., van Berkel T.J., et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 112 (2005) 1054-1062
196. Ma Y., Ma A.G., and Peng Z. A potential immunotherapy approach: mucosal immunization with an IL-13 peptide-based virus-like particle vaccine in a mouse asthma model. Vaccine 25 (2007) 8091-8099
197. Ma Y., Hayglass K.T., Becker A.B., Fan Y., Yang X., Basu S., et al. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med 176 (2007) 439-445
198. Uyttenhove C., and van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 36 (2006) 2868-2874
199. Goldberg R., Zohar Y., Wildbaum G., Geron Y., Maor G., and Karin N. Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27. J Immunol 173 (2004) 6465-6471
200. Goldberg R., Wildbaum G., Zohar Y., Maor G., and Karin N. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J Immunol 173 (2004) 1171-1178
201. Waterston A.M., Salway F., Andreakos E., Butler D.M., Feldmann M., and Coombes R.C. TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br J Cancer 90 (2004) 1279-1284
202. Blank M., Krause I., Wildbaum G., Karin N., and Shoenfeld Y. TNFalpha DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome. Lupus 12 (2003) 546-549
203. Gringeri A., Santagostino E., Mannucci P.M., Siracusano L., Marinoni A., Criscuolo M., et al. Anti-alpha interferon immunization: safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression. Cell Mol Biol (Noisy-le-grand) 41 (1995) 381-387
204. Gringeri A., Santagostino E., Cusini M., Muca-Perja M., Marinoni A., Mannucci P.M., et al. Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report. J Acquir Immune Defic Syndr Hum Retrovirol 13 (1996) 55-67
205. Bizzini B., Volpato I., Lachgar A., Cohen P., and Gringeri A. IFN alpha kinoid vaccine in conjunction with tritherapy, a weapon to combat immunopathogenesis in AIDS. Biomed Pharmacother 53 (1999) 87-89
206. Juji T., Hertz M., Aoki K., Horie D., Ohya K., Gautam A., et al. A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders. J Bone Miner Metab 20 (2002) 266-268
207. Spohn G., and Bachmann M.F. Targeting osteoporosis and rheumatoid arthritis by active vaccination against RANKL. Adv Exp Med Biol 602 (2007) 135-142
208. Youssef S., Maor G., Wildbaum G., Grabie N., Gour-Lavie A., and Karin N. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest 106 (2000) 361-371
209. Youssef S., Wildbaum G., and Karin N. Prevention of experimental autoimmune encephalomyelitis by MIP-1alpha and MCP-1 naked DNA vaccines. J Autoimmunol 13 (1999) 21-29
210. Wildbaum G., Westermann J., Maor G., and Karin N. A targeted DNA vaccine encoding fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis. J Clin Invest 106 (2000) 671-679
211. Onodera S., Ohshima S., Tohyama H., Yasuda K., Nishihira J., Iwakura Y., et al. A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis. Arthritis Rheum 56 (2007) 521-530
212. Tohyama S., Onodera S., Tohyama H., Yasuda K., Nishihira J., Mizue Y., et al. A novel DNA vaccine-targeting macrophage migration inhibitory factor improves the survival of mice with sepsis. Gene Ther 23 (2008) 1513-1522